A Randomized, Double-Blind Placebo- Controlled Phase 2a Study to Assess the Effect of CCR2 Antagonism by MLN1202 on Atherosclerotic Inflammation in Subjects With Stable Atherosclerotic Cardiovascular Disease Using FDG PET/CT Imaging
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 12 Dec 2015
At a glance
- Drugs Plozalizumab (Primary)
- Indications Arteriosclerosis
- Focus Pharmacodynamics
- Sponsors Takeda
- 10 Jun 2017 Biomarkers information updated
- 09 Dec 2015 Status changed from not yet recruiting to withdrawn prior to enrolment, as reported by ClinicalTrials.gov.
- 13 Nov 2015 Planned initiation date changed from 1 May 2015 to 1 Apr 2016, as reported by ClinicalTrials.gov.